Drug maker Merck & Co. Inc. (MRK) will issue it Q2 results on Tuesday, July 30, with analysts polled by Thomson Reuters estimating earnings of $1.16 per share on revenue of $10.96 billion.Year-Ago Numbers:* Sales - $10.5 Bln* GAAP Net Income - $1.71 Bln* GAAP EPS - $0.63* Non-GAAP Net Income - $2.85 Bln* Non-GAAP EPS - $1.06.FY19 Guidance:* Now expects FY19 GAAP EPS in the range of $4.02 - $4.14.* Now estimates FY19 non-GAAP EPS in the range of $4.67 - $4.79; Consensus - $4.75/Shr.* Now expects FY19 revenue between $43.9 Bln and $45.1 Bln; Consensus - $44.74 Bln.Recent Happenings:July 17, Merck said the U.S. Food and Drug Administration has approved Recarbrio (imipenem, cilastatin, and relebactam) for injection, 1.25 grams, a new combination antibacterial. The approval is for treatment of adults with complicated urinary tract and complicated intra-abdominal bacterial infections where limited or no alternative treatment options are available.June 18, Merck reported that FDA has accelerated approval for KEYTRUDA as monotherapy for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. The approval was based on pooled data from KEYNOTE-158 and KEYNOTE-028 open-label trials.May 21, Merck said it agreed to acquire Peloton Therapeutics Inc. for an upfront payment of $1.05 billion. Peloton shareholders would receive a further $1.15 billion on achievement of certain milestones.